VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q73587266 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241020233045.0
008 241020nneanz||abbn n and d
035 ‎‡a (WKP)Q73587266‏
024 ‎‡a 0000-0003-0013-620X‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q73587266‏
100 0 ‎‡a Anna Lena Lopez‏ ‎‡c researcher‏ ‎‡9 en‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
400 0 ‎‡a A L Lopez‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.‏
670 ‎‡a Author's A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India‏
670 ‎‡a Author's An overview of the status of acellular pertussis vaccines in practice.‏
670 ‎‡a Author's Assessing different measures of population-level vaccine protection using a case-control study.‏
670 ‎‡a Author's Burden of pneumonia and meningitis caused by Streptococcus pneumoniae in China among children under 5 years of age: a systematic literature review‏
670 ‎‡a Author's Cholera in India: an analysis of reports, 1997-2006‏
670 ‎‡a Author's Cholera outbreak in Yemen‏
670 ‎‡a Author's Cholera outbreaks caused by an altered Vibrio cholerae O1 El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007 to 2008.‏
670 ‎‡a Author's Cholera prevention and control in Asian countries‏
670 ‎‡a Author's Cholera vaccines for the developing world.‏
670 ‎‡a Author's Classification of hybrid and altered Vibrio cholerae strains by CTX prophage and RS1 element structure.‏
670 ‎‡a Author's Correction: Evaluation in Cameroon of a Novel, Simplified Methodology to Assist Molecular Microbiological Analysis of V. cholerae in Resource-Limited Settings‏
670 ‎‡a Author's Correction: Risk Map of Cholera Infection for Vaccine Deployment: The Eastern Kolkata Case.‏
670 ‎‡a Author's Effect of heat inactivation of serum on Bordetella pertussis antibody determination by enzyme-linked immunosorbent assay‏
670 ‎‡a Author's Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study‏
670 ‎‡a Author's Effectiveness of monovalent rotavirus vaccine in the Philippines‏
670 ‎‡a Author's Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial‏
670 ‎‡a Author's Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial‏
670 ‎‡a Author's Epidemiology of cholera in the Philippines‏
670 ‎‡a Author's Epidemiology of Japanese encephalitis in the Philippines: a systematic review‏
670 ‎‡a Author's Evaluation in Cameroon of a Novel, Simplified Methodology to Assist Molecular Microbiological Analysis of V. cholerae in Resource-Limited Settings.‏
670 ‎‡a Author's Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone.‏
670 ‎‡a Author's Hepatitis B seroprevalence among 5 to 6 years old children in the Philippines born prior to routine hepatitis B vaccination at birth‏
670 ‎‡a Author's Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India.‏
670 ‎‡a Author's Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial‏
670 ‎‡a Author's Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis‏
670 ‎‡a Author's Impact of rotavirus vaccine on diarrheal hospitalization and outpatient consultations in the Philippines: First evidence from a middle-income Asian country.‏
670 ‎‡a Author's Improving rotavirus vaccine coverage: Can newer-generation and locally produced vaccines help?‏
670 ‎‡a Author's Introduction of inactivated poliovirus vaccine in the Philippines: Effect on health care provider and infant caregiver attitudes and practices‏
670 ‎‡a Author's Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.‏
670 ‎‡a Author's Oral cholera vaccine development and use in Vietnam‏
670 ‎‡a Author's Oral cholera vaccines--a call for action‏
670 ‎‡a Author's Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania‏
670 ‎‡a Author's Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand‏
670 ‎‡a Author's Post-licensure deployment of oral cholera vaccines: a systematic review‏
670 ‎‡a Author's Prospects for rotavirus vaccine introduction in the Philippines: Bridging the available evidence into immunization policy‏
670 ‎‡a Author's Ranitidine and late-onset sepsis in the neonatal intensive care unit‏
670 ‎‡a Author's Risk map of cholera infection for vaccine deployment: the eastern Kolkata case.‏
670 ‎‡a Author's Rubella and Congenital Rubella Syndrome in the Philippines: A Systematic Review.‏
670 ‎‡a Author's Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.‏
670 ‎‡a Author's Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy‏
670 ‎‡a Author's Surveillance for tuberculosis in a rural community in The Philippines.‏
670 ‎‡a Author's The burden of congenital rubella syndrome in the Philippines: results from a retrospective assessment‏
670 ‎‡a Author's The global burden of cholera.‏
670 ‎‡a Author's The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa‏
670 ‎‡a Author's The scenario approach for countries considering the addition of oral cholera vaccination in cholera preparedness and control plans‏
670 ‎‡a Author's Trials and tribulations of conducting interventional studies in urban slums of a developing country: Experiences from Kolkata, India‏
670 ‎‡a Author's Updated global burden of cholera in endemic countries‏
670 ‎‡a Author's Urine Xpert MTB/RIF for the diagnosis of childhood tuberculosis‏
670 ‎‡a Author's Use of oral cholera vaccines in an outbreak in Vietnam: a case control study.‏
670 ‎‡a Author's Use of verbal autopsy to determine mortality patterns in an urban slum in Kolkata, India.‏
670 ‎‡a Author's Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission.‏
670 ‎‡a Author's Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design‏
670 ‎‡a Author's Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India‏
909 ‎‡a (orcid) 000000030013620x‏ ‎‡9 1‏
919 ‎‡a hepatitisbseroprevalenceamong5to6yearsoldchildreninthephilippinesbornpriortoroutinehepatitisbvaccinationatbirth‏ ‎‡A Hepatitis B seroprevalence among 5 to 6 years old children in the Philippines born prior to routine hepatitis B vaccination at birth‏ ‎‡9 1‏
919 ‎‡a epidemiologyofcholerainthephilippines‏ ‎‡A Epidemiology of cholera in the Philippines‏ ‎‡9 1‏
919 ‎‡a epidemiologyofjapaneseencephalitisinthephilippinesasystematicreview‏ ‎‡A Epidemiology of Japanese encephalitis in the Philippines: a systematic review‏ ‎‡9 1‏
919 ‎‡a flexibilityoforalcholeravaccinedosingarandomizedcontrolledtrialmeasuringimmuneresponsesfollowingalternativevaccinationschedulesinacholerahyperendemiczone‏ ‎‡A Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone.‏ ‎‡9 1‏
919 ‎‡a evaluationincameroonofanovelsimplifiedmethodologytoassistmolecularmicrobiologicalanalysisof5choleraeinresourcelimitedsettings‏ ‎‡A Evaluation in Cameroon of a Novel, Simplified Methodology to Assist Molecular Microbiological Analysis of V. cholerae in Resource-Limited Settings.‏ ‎‡9 1‏
919 ‎‡a introductionofinactivatedpoliovirusvaccineinthephilippineseffectonhealthcareproviderandinfantcaregiverattitudesandpractices‏ ‎‡A Introduction of inactivated poliovirus vaccine in the Philippines: Effect on health care provider and infant caregiver attitudes and practices‏ ‎‡9 1‏
919 ‎‡a massvaccinationwithanewlessexpensiveoralcholeravaccineusingpublichealthinfrastructureinindiatheodishamodel‏ ‎‡A Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.‏ ‎‡9 1‏
919 ‎‡a oralcholeravaccinedevelopmentanduseinvietnam‏ ‎‡A Oral cholera vaccine development and use in Vietnam‏ ‎‡9 1‏
919 ‎‡a globalburdenofcholera‏ ‎‡A The global burden of cholera.‏ ‎‡9 1‏
919 ‎‡a useofverbalautopsytodeterminemortalitypatternsinanurbansluminkolkataindia‏ ‎‡A Use of verbal autopsy to determine mortality patterns in an urban slum in Kolkata, India.‏ ‎‡9 1‏
919 ‎‡a validityoftheestimatesoforalcholeravaccineeffectivenessderivedfromthetestnegativedesign‏ ‎‡A Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design‏ ‎‡9 1‏
919 ‎‡a vibriocidalantibodyresponsestoabivalentkilledwholecelloralcholeravaccineinaphase3trialinkolkataindia‏ ‎‡A Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India‏ ‎‡9 1‏
919 ‎‡a 5yearefficacyofabivalentkilledwholecelloralcholeravaccineinkolkataindiaaclusterrandomiseddoubleblindplacebocontrolledtrial‏ ‎‡A 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial.‏ ‎‡9 1‏
919 ‎‡a randomizedplacebocontrolledtrialofthebivalentkilledwholecelloralcholeravaccineinadultsandchildreninacholeraendemicareainkolkataindia‏ ‎‡A A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India‏ ‎‡9 1‏
919 ‎‡a overviewofthestatusofacellularpertussisvaccinesinpractice‏ ‎‡A An overview of the status of acellular pertussis vaccines in practice.‏ ‎‡9 1‏
919 ‎‡a assessingdifferentmeasuresofpopulationlevelvaccineprotectionusingacasecontrolstudy‏ ‎‡A Assessing different measures of population-level vaccine protection using a case-control study.‏ ‎‡9 1‏
919 ‎‡a burdenofpneumoniaandmeningitiscausedbystreptococcuspneumoniaeinchinaamongchildrenunder5yearsofageasystematicliteraturereview‏ ‎‡A Burden of pneumonia and meningitis caused by Streptococcus pneumoniae in China among children under 5 years of age: a systematic literature review‏ ‎‡9 1‏
919 ‎‡a cholerainindiaananalysisofreports1997‏ ‎‡A Cholera in India: an analysis of reports, 1997-2006‏ ‎‡9 1‏
919 ‎‡a choleraoutbreakinyemen‏ ‎‡A Cholera outbreak in Yemen‏ ‎‡9 1‏
919 ‎‡a choleraoutbreakscausedbyanalteredvibriocholeraeo1eltorbiotypestrainproducingclassicalcholeratoxinbinvietnamin2007to‏ ‎‡A Cholera outbreaks caused by an altered Vibrio cholerae O1 El Tor biotype strain producing classical cholera toxin B in Vietnam in 2007 to 2008.‏ ‎‡9 1‏
919 ‎‡a oralcholeravaccinesacallforaction‏ ‎‡A Oral cholera vaccines--a call for action‏ ‎‡9 1‏
919 ‎‡a cholerapreventionandcontrolinasiancountries‏ ‎‡A Cholera prevention and control in Asian countries‏ ‎‡9 1‏
919 ‎‡a choleravaccinesforthedevelopingworld‏ ‎‡A Cholera vaccines for the developing world.‏ ‎‡9 1‏
919 ‎‡a classificationofhybridandalteredvibriocholeraestrainsbyctxprophageandrs1elementstructure‏ ‎‡A Classification of hybrid and altered Vibrio cholerae strains by CTX prophage and RS1 element structure.‏ ‎‡9 1‏
919 ‎‡a correctionevaluationincameroonofanovelsimplifiedmethodologytoassistmolecularmicrobiologicalanalysisof5choleraeinresourcelimitedsettings‏ ‎‡A Correction: Evaluation in Cameroon of a Novel, Simplified Methodology to Assist Molecular Microbiological Analysis of V. cholerae in Resource-Limited Settings‏ ‎‡9 1‏
919 ‎‡a correctionriskmapofcholerainfectionforvaccinedeploymenttheeasternkolkatacase‏ ‎‡A Correction: Risk Map of Cholera Infection for Vaccine Deployment: The Eastern Kolkata Case.‏ ‎‡9 1‏
919 ‎‡a paperlessregistrationduringsurveyenumerationsandlargeoralcholeramassvaccinationinzanzibartheunitedrepublicoftanzania‏ ‎‡A Paperless registration during survey enumerations and large oral cholera mass vaccination in Zanzibar, the United Republic of Tanzania‏ ‎‡9 1‏
919 ‎‡a highburdenofcholerainchildrencomparisonofincidencefromendemicareasinasiaandafrica‏ ‎‡A The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa‏ ‎‡9 1‏
919 ‎‡a peru15choleragardealiveattenuatedoralcholeravaccineissafeandimmunogenicinhumanimmunodeficiencyvirushivseropositiveadultsinthailand‏ ‎‡A Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand‏ ‎‡9 1‏
919 ‎‡a postlicensuredeploymentoforalcholeravaccinesasystematicreview‏ ‎‡A Post-licensure deployment of oral cholera vaccines: a systematic review‏ ‎‡9 1‏
919 ‎‡a prospectsforrotavirusvaccineintroductioninthephilippinesbridgingtheavailableevidenceintoimmunizationpolicy‏ ‎‡A Prospects for rotavirus vaccine introduction in the Philippines: Bridging the available evidence into immunization policy‏ ‎‡9 1‏
919 ‎‡a ranitidineandlateonsetsepsisintheneonatalintensivecareunit‏ ‎‡A Ranitidine and late-onset sepsis in the neonatal intensive care unit‏ ‎‡9 1‏
919 ‎‡a riskmapofcholerainfectionforvaccinedeploymenttheeasternkolkatacase‏ ‎‡A Risk map of cholera infection for vaccine deployment: the eastern Kolkata case.‏ ‎‡9 1‏
919 ‎‡a rubellaandcongenitalrubellasyndromeinthephilippinesasystematicreview‏ ‎‡A Rubella and Congenital Rubella Syndrome in the Philippines: A Systematic Review.‏ ‎‡9 1‏
919 ‎‡a scenarioapproachforcountriesconsideringtheadditionoforalcholeravaccinationincholerapreparednessandcontrolplans‏ ‎‡A The scenario approach for countries considering the addition of oral cholera vaccination in cholera preparedness and control plans‏ ‎‡9 1‏
919 ‎‡a safetyandimmunogenicityofareformulatedvietnamesebivalentkilledwholecelloralcholeravaccineinadults‏ ‎‡A Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.‏ ‎‡9 1‏
919 ‎‡a trialsandtribulationsofconductinginterventionalstudiesinurbanslumsofadevelopingcountryexperiencesfromkolkataindia‏ ‎‡A Trials and tribulations of conducting interventional studies in urban slums of a developing country: Experiences from Kolkata, India‏ ‎‡9 1‏
919 ‎‡a updatedglobalburdenofcholerainendemiccountries‏ ‎‡A Updated global burden of cholera in endemic countries‏ ‎‡9 1‏
919 ‎‡a safetyoftherecombinantcholeratoxinbsubunitkilledwholecellrbswcoralcholeravaccineinpregnancy‏ ‎‡A Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy‏ ‎‡9 1‏
919 ‎‡a urinexpertmtbrifforthediagnosisofchildhoodtuberculosis‏ ‎‡A Urine Xpert MTB/RIF for the diagnosis of childhood tuberculosis‏ ‎‡9 1‏
919 ‎‡a vaccineprotectionofbangladeshiinfantsandyoungchildrenagainstcholeraimplicationsforvaccinedeploymentandpersontopersontransmission‏ ‎‡A Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission.‏ ‎‡9 1‏
919 ‎‡a impactofrotavirusvaccineondiarrhealhospitalizationandoutpatientconsultationsinthephilippines1evidencefromamiddleincomeasiancountry‏ ‎‡A Impact of rotavirus vaccine on diarrheal hospitalization and outpatient consultations in the Philippines: First evidence from a middle-income Asian country.‏ ‎‡9 1‏
919 ‎‡a improvingrotavirusvaccinecoveragecannewergenerationandlocallyproducedvaccineshelp‏ ‎‡A Improving rotavirus vaccine coverage: Can newer-generation and locally produced vaccines help?‏ ‎‡9 1‏
919 ‎‡a immunogenicityandprotectionfromasingledoseofinternationallyavailablekilledoralcholeravaccineasystematicreviewandmetaanalysis‏ ‎‡A Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis‏ ‎‡9 1‏
919 ‎‡a surveillancefortuberculosisinaruralcommunityinthephilippines‏ ‎‡A Surveillance for tuberculosis in a rural community in The Philippines.‏ ‎‡9 1‏
919 ‎‡a burdenofcongenitalrubellasyndromeinthephilippinesresultsfromaretrospectiveassessment‏ ‎‡A The burden of congenital rubella syndrome in the Philippines: results from a retrospective assessment‏ ‎‡9 1‏
919 ‎‡a immuneresponsesfollowing1and2dosesofthereformulatedbivalentkilledwholecelloralcholeravaccineamongadultsandchildreninkolkataindiaarandomizedplacebocontrolledtrial‏ ‎‡A Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial‏ ‎‡9 1‏
919 ‎‡a herdprotectionbyabivalentkilledwholecelloralcholeravaccineintheslumsofkolkataindia‏ ‎‡A Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India.‏ ‎‡9 1‏
919 ‎‡a effectofheatinactivationofserumonbordetellapertussisantibodydeterminationbyenzymelinkedimmunosorbentassay‏ ‎‡A Effect of heat inactivation of serum on Bordetella pertussis antibody determination by enzyme-linked immunosorbent assay‏ ‎‡9 1‏
919 ‎‡a effectivenessofanoralcholeravaccineinzanzibarfindingsfromamassvaccinationcampaignandobservationalcohortstudy‏ ‎‡A Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study‏ ‎‡9 1‏
919 ‎‡a effectivenessofmonovalentrotavirusvaccineinthephilippines‏ ‎‡A Effectiveness of monovalent rotavirus vaccine in the Philippines‏ ‎‡9 1‏
919 ‎‡a efficacyandsafetyofamodifiedkilledwholecelloralcholeravaccineinindiaaninterimanalysisofaclusterrandomiseddoubleblindplacebocontrolledtrial‏ ‎‡A Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial‏ ‎‡9 1‏
919 ‎‡a efficacyofalowcostinactivatedwholecelloralcholeravaccineresultsfrom3yearsoffollowupofarandomizedcontrolledtrial‏ ‎‡A Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial‏ ‎‡9 1‏
919 ‎‡a useoforalcholeravaccinesinanoutbreakinvietnamacasecontrolstudy‏ ‎‡A Use of oral cholera vaccines in an outbreak in Vietnam: a case control study.‏ ‎‡9 1‏
943 ‎‡a 200x‏ ‎‡A 2006‏ ‎‡9 2‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 SUDOC|156532832‏
996 ‎‡2 BNC|981058524386506706‏
996 ‎‡2 PLWABN|9810680279405606‏
996 ‎‡2 BNC|981058608231706706‏
996 ‎‡2 BNF|12324302‏
996 ‎‡2 LC|no2013001476‏
996 ‎‡2 BNC|981058518321906706‏
996 ‎‡2 RERO|A003541388‏
996 ‎‡2 LC|n 2014046997‏
996 ‎‡2 ISNI|0000000061016664‏
996 ‎‡2 ISNI|0000000059491730‏
996 ‎‡2 LC|n 98054020‏
996 ‎‡2 LC|no2017028951‏
996 ‎‡2 BNE|XX1076919‏
996 ‎‡2 BNE|XX927548‏
996 ‎‡2 NUKAT|n 2007008455‏
996 ‎‡2 DNB|129757799‏
996 ‎‡2 DNB|1266648119‏
996 ‎‡2 BNE|XX5230077‏
996 ‎‡2 LC|n 2018060432‏
996 ‎‡2 DNB|1056625767‏
996 ‎‡2 SUDOC|080480241‏
996 ‎‡2 DNB|1203247397‏
996 ‎‡2 BNE|XX6067871‏
996 ‎‡2 ISNI|0000000052761793‏
996 ‎‡2 LC|no2003059884‏
996 ‎‡2 SUDOC|151811946‏
996 ‎‡2 LC|no2021105005‏
996 ‎‡2 BNE|XX879120‏
996 ‎‡2 BNE|XX5184141‏
996 ‎‡2 BNC|981058522911006706‏
996 ‎‡2 KRNLK|KAC202319011‏
996 ‎‡2 LC|n 2003029771‏
996 ‎‡2 SUDOC|03263854X‏
996 ‎‡2 BNC|981058514783606706‏
996 ‎‡2 BNE|XX819581‏
996 ‎‡2 ISNI|0000000060081499‏
996 ‎‡2 ISNI|0000000059764014‏
996 ‎‡2 BIBSYS|9043902‏
996 ‎‡2 LC|no2019014990‏
996 ‎‡2 RERO|A013323759‏
996 ‎‡2 SUDOC|159175305‏
996 ‎‡2 ISNI|000000045963290X‏
996 ‎‡2 ISNI|0000000355779229‏
996 ‎‡2 ISNI|0000000511667086‏
996 ‎‡2 ISNI|0000000120053124‏
996 ‎‡2 LC|no2022033862‏
996 ‎‡2 ISNI|0000000060964590‏
996 ‎‡2 BNE|XX6305530‏
996 ‎‡2 BNF|17051140‏
996 ‎‡2 ISNI|0000000500075659‏
996 ‎‡2 NDL|033538258‏
996 ‎‡2 LC|no2010154985‏
996 ‎‡2 BNE|XX4924255‏
996 ‎‡2 CAOONL|ncf10728450‏
996 ‎‡2 BNE|XX1250895‏
996 ‎‡2 LC|nb2004007158‏
996 ‎‡2 ISNI|0000000374652100‏
996 ‎‡2 ISNI|0000000059845076‏
996 ‎‡2 BNE|XX863341‏
996 ‎‡2 NTA|100828957‏
996 ‎‡2 BNE|XX1126380‏
996 ‎‡2 SUDOC|094180539‏
996 ‎‡2 DNB|1221759485‏
996 ‎‡2 CAOONL|ncf11541882‏
996 ‎‡2 LNB|LNC10-000256057‏
996 ‎‡2 BNE|XX1050653‏
996 ‎‡2 RERO|A000108039‏
996 ‎‡2 LC|no2017001528‏
996 ‎‡2 DNB|1057376043‏
996 ‎‡2 BIBSYS|90210410‏
996 ‎‡2 NUKAT|n 2011174105‏
996 ‎‡2 BNC|981058514341906706‏
996 ‎‡2 ISNI|0000000117277354‏
996 ‎‡2 LC|no2020074141‏
996 ‎‡2 LC|n 2014054233‏
996 ‎‡2 ISNI|0000000071426085‏
996 ‎‡2 NTA|269463380‏
996 ‎‡2 BNE|XX4881694‏
996 ‎‡2 ISNI|0000000079754294‏
996 ‎‡2 LC|n 2023057410‏
996 ‎‡2 CAOONL|ncf10326394‏
996 ‎‡2 BNE|XX1093658‏
996 ‎‡2 BNE|XX1617516‏
996 ‎‡2 SUDOC|055277438‏
996 ‎‡2 LC|n 83125203‏
996 ‎‡2 LC|no2010025344‏
996 ‎‡2 BNC|981060788405206706‏
996 ‎‡2 LC|no2016070731‏
996 ‎‡2 BNCHL|10000000000000000159818‏
996 ‎‡2 RERO|A027483643‏
996 ‎‡2 BNE|XX1688888‏
996 ‎‡2 BNC|981058522596706706‏
996 ‎‡2 ISNI|0000000138814307‏
996 ‎‡2 BNF|16207530‏
996 ‎‡2 BNE|XX1135241‏
996 ‎‡2 BNE|XX1708752‏
996 ‎‡2 ISNI|000000004033994X‏
996 ‎‡2 LC|no2001058593‏
996 ‎‡2 DNB|1346909970‏
996 ‎‡2 ISNI|0000000077680199‏
996 ‎‡2 DNB|137919166‏
996 ‎‡2 ISNI|0000000116969623‏
996 ‎‡2 BNC|981058514417906706‏
996 ‎‡2 DNB|1240630166‏
996 ‎‡2 LC|no2024059265‏
996 ‎‡2 ISNI|0000000040006897‏
996 ‎‡2 LC|ns2013002836‏
996 ‎‡2 SUDOC|259036668‏
996 ‎‡2 SUDOC|112337813‏
996 ‎‡2 SUDOC|197710727‏
996 ‎‡2 SUDOC|193430495‏
996 ‎‡2 BNE|XX4686932‏
996 ‎‡2 LC|nr 96039568‏
996 ‎‡2 ISNI|0000000072174289‏
996 ‎‡2 BNE|XX4773794‏
996 ‎‡2 NTA|303514612‏
996 ‎‡2 ISNI|0000000118717796‏
996 ‎‡2 BNE|XX973985‏
996 ‎‡2 SUDOC|093146612‏
996 ‎‡2 J9U|987007392950005171‏
996 ‎‡2 DE633|pe30101119‏
996 ‎‡2 LC|n 2006096339‏
996 ‎‡2 BNC|981058524064706706‏
996 ‎‡2 ISNI|0000000023729743‏
996 ‎‡2 CAOONL|ncf13746753‏
996 ‎‡2 LC|no2014018911‏
996 ‎‡2 SUDOC|127106006‏
996 ‎‡2 ISNI|0000000498917828‏
996 ‎‡2 LC|nr 97027383‏
996 ‎‡2 BNCHL|10000000000000000094012‏
996 ‎‡2 J9U|987011196678105171‏
996 ‎‡2 DNB|106300859X‏
996 ‎‡2 ISNI|0000000059197144‏
996 ‎‡2 LC|n 2002095308‏
996 ‎‡2 ISNI|0000000028644255‏
996 ‎‡2 LC|no2011148906‏
996 ‎‡2 BIBSYS|90878816‏
996 ‎‡2 BNF|17753417‏
996 ‎‡2 ISNI|0000000060316390‏
996 ‎‡2 LC|n 2012046490‏
996 ‎‡2 LC|n 80045805‏
996 ‎‡2 LC|ns2019002341‏
996 ‎‡2 NLR|RU NLR AUTH 770185524‏
996 ‎‡2 BNC|981058509633206706‏
996 ‎‡2 LC|no2020127001‏
996 ‎‡2 BNC|981058611509806706‏
996 ‎‡2 BNE|XX4661475‏
996 ‎‡2 NUKAT|n 2004045441‏
996 ‎‡2 NTA|416655602‏
996 ‎‡2 DNB|1282560387‏
996 ‎‡2 BNE|XX4441874‏
996 ‎‡2 ISNI|0000000077278407‏
996 ‎‡2 NTA|069986711‏
996 ‎‡2 J9U|987012502617805171‏
996 ‎‡2 KRNLK|KAC202319049‏
996 ‎‡2 ICCU|CFIV202549‏
996 ‎‡2 LC|nr 93021711‏
996 ‎‡2 SUDOC|276533313‏
996 ‎‡2 LC|ns2022000467‏
996 ‎‡2 BIBSYS|10073172‏
996 ‎‡2 DNB|1136338853‏
996 ‎‡2 LC|n 2006089369‏
996 ‎‡2 ISNI|0000000500559514‏
996 ‎‡2 BNE|XX1053091‏
996 ‎‡2 ISNI|000000008005982X‏
996 ‎‡2 BNC|981058513809406706‏
996 ‎‡2 SUDOC|192836676‏
996 ‎‡2 LC|no2024025595‏
996 ‎‡2 BNE|XX5661945‏
996 ‎‡2 BNF|16563430‏
996 ‎‡2 ISNI|0000000060156454‏
996 ‎‡2 BNE|XX4580971‏
996 ‎‡2 LC|no2014036453‏
996 ‎‡2 LC|no2021000794‏
996 ‎‡2 ISNI|0000000506329330‏
996 ‎‡2 ISNI|0000000059410136‏
996 ‎‡2 BNC|981058522916906706‏
996 ‎‡2 BNE|XX5078034‏
996 ‎‡2 DNB|1014774918‏
996 ‎‡2 LC|no2009063503‏
996 ‎‡2 DNB|1036547175‏
996 ‎‡2 SUDOC|069364559‏
996 ‎‡2 ISNI|0000000399836045‏
996 ‎‡2 ISNI|0000000079741012‏
996 ‎‡2 LC|no2020144281‏
996 ‎‡2 ISNI|0000000060744838‏
996 ‎‡2 LC|n 90643545‏
996 ‎‡2 SUDOC|227923081‏
996 ‎‡2 BNF|17999883‏
996 ‎‡2 BNE|XX1724300‏
996 ‎‡2 ISNI|0000000080980184‏
996 ‎‡2 BNE|XX1005903‏
996 ‎‡2 LC|n 2014077027‏
996 ‎‡2 LC|nb2011014026‏
996 ‎‡2 ISNI|0000000116184455‏
996 ‎‡2 RERO|A023202753‏
996 ‎‡2 ISNI|0000000071934995‏
996 ‎‡2 ISNI|0000000503823106‏
996 ‎‡2 LC|no2011174673‏
996 ‎‡2 ISNI|0000000113182067‏
996 ‎‡2 DNB|1141603004‏
996 ‎‡2 LC|no2019164080‏
996 ‎‡2 PLWABN|9810572184305606‏
996 ‎‡2 NII|DA04919704‏
996 ‎‡2 BNC|981058618248606706‏
996 ‎‡2 BNE|XX894843‏
996 ‎‡2 BNF|16036451‏
996 ‎‡2 BNE|XX1648696‏
996 ‎‡2 SZ|129757799‏
996 ‎‡2 NSK|000657733‏
996 ‎‡2 PTBNP|1657759‏
996 ‎‡2 CAOONL|ncf11324609‏
996 ‎‡2 BNE|XX1746007‏
996 ‎‡2 NKC|xx0233856‏
996 ‎‡2 LC|n 85349837‏
996 ‎‡2 LC|n 2001000730‏
996 ‎‡2 SUDOC|253878829‏
996 ‎‡2 RERO|A000066196‏
996 ‎‡2 ISNI|0000000107931500‏
996 ‎‡2 DNB|119358521X‏
996 ‎‡2 BNC|981058524383806706‏
996 ‎‡2 ISNI|0000000393595092‏
996 ‎‡2 RERO|A003541218‏
996 ‎‡2 BNC|981058601418106706‏
996 ‎‡2 PTBNP|1437258‏
996 ‎‡2 SUDOC|261020145‏
996 ‎‡2 DNB|1164254693‏
996 ‎‡2 ISNI|0000000073526741‏
996 ‎‡2 BNE|XX1063721‏
996 ‎‡2 DNB|1223656187‏
996 ‎‡2 NTA|250212145‏
996 ‎‡2 LC|ns2014002081‏
996 ‎‡2 BNC|981058529596906706‏
996 ‎‡2 BIBSYS|1038681‏
996 ‎‡2 SUDOC|091234301‏
996 ‎‡2 LC|no2014020067‏
996 ‎‡2 LC|ns2016003942‏
996 ‎‡2 LC|ns2014000972‏
996 ‎‡2 LC|no2017019084‏
996 ‎‡2 BNC|981058617366506706‏
996 ‎‡2 ISNI|0000000111120372‏
996 ‎‡2 BNE|XX1318395‏
996 ‎‡2 BNF|16387490‏
996 ‎‡2 DNB|128862726‏
996 ‎‡2 BNCHL|10000000000000000179496‏
996 ‎‡2 NKC|mzk2015860157‏
996 ‎‡2 LC|ns2021002221‏
996 ‎‡2 BNE|XX1618834‏
996 ‎‡2 PLWABN|9810689433605606‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏